Lipid Modification Therapy for Preventing Cardiovascular Disease

Objectives

The pathway provides a National Institute for Health and Care Excellence (NICE) framework for lipid modification to prevent cardiovascular disease, covering primary and secondary prevention and prioritising treatments with clinical-trial evidence of benefit for cardiovascular morbidity and mortality. It aims to reduce cardiovascular risk through individual risk assessment, lifestyle modification, informed statin decisions and escalation to other lipid-lowering therapies where statins are contraindicated, not tolerated or insufficiently effective.[1][2][3]

• Identify high cardiovascular risk in people with acute coronary syndrome, revascularisation, coronary heart disease, ischaemic stroke or peripheral arterial disease, and identify very high risk where recurrent events or polyvascular disease are present.[4]
• Promote lifestyle advice, exclusion of secondary causes of dyslipidaemia and discussion of the benefits and risks of statins as core quality priorities for prevention.[5][2]
• Offer statins for eligible primary prevention, including people with a 10-year cardiovascular disease risk of 10% or more and relevant groups with diabetes, while using high-intensity treatment for secondary prevention where appropriate.[2][6]
• Support treatment for people with chronic kidney disease, including atorvastatin for primary or secondary prevention and specialist agreement on higher doses when renal function is substantially reduced.[6][7]
• Manage statin intolerance by seeking the maximum tolerated dose and using treatment adjustment, alternative statins, ezetimibe or specialist advice according to cardiovascular risk and treatment response.[7][8]
• Enable additional lipid-lowering options, including bempedoic acid with ezetimibe, evolocumab and alirocumab, for defined populations with persistent low-density lipoprotein cholesterol elevation despite maximal tolerated therapy or where statins cannot be used.[3][9]
• Avoid routine use of fibrates, nicotinic acid, bile acid sequestrants, omega-3 fatty acid compounds, coenzyme Q10 and vitamin D for the specified prevention or statin-adherence purposes.[2]

Implementation

Implementation centres on shared decision-making between clinicians and patients, supported by cardiovascular risk assessment, baseline testing, proportionate follow-up and selection of clinically appropriate medicines at low acquisition cost where this is specified. Healthcare commissioners and providers enable local delivery in line with local and national funding and service-development priorities, while professionals retain responsibility for decisions suited to individual circumstances.[1][4][10]

• Assess 10-year cardiovascular disease risk using QRISK2 for primary prevention, and offer atorvastatin 20 mg when risk is 10% or greater, including eligible people with type 2 diabetes.[2][6]
• Consider statins for adults with type 1 diabetes and offer atorvastatin 20 mg for those aged over 40 years, with diabetes duration exceeding 10 years, established nephropathy or other cardiovascular risk factors.[6]
• Start atorvastatin 80 mg for secondary prevention in people with cardiovascular disease, while using a lower dose when interactions, adverse-effect risk or patient preference warrant this.[6]
• Discuss treatment benefits and risks, lifestyle benefits, preferences, comorbidities, polypharmacy, frailty and life expectancy before initiating a statin, and provide a decision aid where relevant.[1]
• Assess smoking, alcohol use, blood pressure, obesity, lipid profile, glycated haemoglobin, renal function, liver transaminases and thyroid-stimulating hormone before treatment, while addressing comorbidities and secondary causes of dyslipidaemia.[1]
• Check for a history of unexplained generalised muscle pain and measure creatine kinase when indicated; do not initiate a statin if repeat testing confirms creatine kinase above five times the upper limit of normal.[5]
• Avoid routinely excluding people from statin treatment solely because liver transaminases are below three times the upper limit of normal.[5]
• Advise patients about interactions with medicines, foods and supplements, use patient information or pharmacy and prescriber support, and advise prompt medical review for muscle symptoms.[2]
• Address pregnancy risks by advising women who may become pregnant to stop statins if pregnancy is possible, and by stopping treatment three months before planned conception until breastfeeding has ended.[2]
• Manage adverse effects by considering temporary discontinuation and rechallenge, dose reduction or a lower-intensity statin, and seek specialist advice for high-risk people unable to tolerate three different statins.[7]
• Use ezetimibe monotherapy when statins are contraindicated or not tolerated, and consider ezetimibe with a statin when lipid control remains inadequate or statin titration is limited by intolerance.[8][3]
• Prescribe high-intensity statins and statin-ezetimibe combinations on the basis of low or lowest acquisition cost where clinically suitable.[1][8][3]
• Offer bempedoic acid with ezetimibe as an adjunct to diet under the applicable commercial arrangement when statins are contraindicated or not tolerated and ezetimibe alone is insufficient.[3]
• Use evolocumab or alirocumab only for people meeting the relevant diagnosis, cardiovascular risk and persistent low-density lipoprotein cholesterol thresholds despite maximal tolerated lipid-lowering therapy, subject to the relevant patient access arrangements.[3][9]
• Review lipid response three months after initiating high-intensity statin therapy and aim for a reduction exceeding 40% in non-high-density lipoprotein cholesterol; review adherence, dose timing, diet and lifestyle, and consider dose escalation for higher-risk people when this is not achieved.[8]
• Provide annual medication reviews covering adherence, lifestyle modification and cardiovascular risk factors, and consider annual non-fasting non-high-density lipoprotein cholesterol testing.[8]
• Apply equality duties by addressing unlawful discrimination, advancing equality of opportunity and reducing health inequalities, and consider environmental impacts in local implementation.[10]

Monitoring & Evaluation

Monitoring centres on baseline clinical assessment, cardiovascular risk estimation, lipid response, adverse effects and periodic medication review. The supplied material identifies quality standards and National Institute for Health and Care Excellence guidance as relevant assurance mechanisms, but does not establish a unified reporting, surveillance or independent evaluation framework.[1][5][2][6][7][8][3][9]

• Assess cardiovascular risk for primary prevention using the QRISK2 tool, alongside smoking, alcohol use, blood pressure, obesity, lipid profile, glycated haemoglobin, renal function, liver transaminases and thyroid-stimulating hormone.[1][2][6]
• Exclude or address secondary causes of dyslipidaemia and comorbidities before or alongside lipid-modifying treatment, supported by quality statements on secondary-cause exclusion and lifestyle advice.[1][5][2]
• Measure baseline lipid values, glycated haemoglobin, renal function, estimated glomerular filtration rate and liver transaminases before treatment.[1][5]
• Measure creatine kinase when persistent unexplained generalised muscle pain is reported before treatment, or when muscle pain, tenderness or weakness develops during statin treatment; do not routinely measure it in asymptomatic people.[5][2][7][8]
• Monitor liver transaminases within three months of commencing treatment and at 12 months, with additional tests only where clinically indicated.[7][8]
• Measure total cholesterol, high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol three months after starting high-intensity statin treatment, including atorvastatin 20 mg for primary prevention.[8]
• Aim for a reduction of more than 40% in non-high-density lipoprotein cholesterol, including for people with chronic kidney disease; where this is not achieved, review adherence and dose timing, optimise diet and lifestyle measures, and consider dose escalation for people at higher risk, subject to renal function and specialist agreement.[6][7][8]
• Provide annual medication reviews covering adherence, lifestyle modification and cardiovascular risk factors, and consider annual non-fasting non-high-density lipoprotein cholesterol testing.[8]
• Verify persistent low-density lipoprotein cholesterol elevation above the applicable threshold, and confirm maximal tolerated lipid-lowering therapy or intolerance-limited titration, when considering alirocumab or evolocumab.[3][9]
• Use individual risk assessment and relevant national cardiovascular disease guidance to judge whether cholesterol is appropriately controlled.[3]

The material does not specify numerical service-performance indicators, a reporting timetable, routine population surveillance, named accountability bodies, or an independent evaluation process.[1][5][2][6][3][9][4][10]

Costing & Financing

Resource considerations are principally expressed as medicine-selection and access arrangements rather than quantified programme budgets. Prescribers should use low or lowest acquisition cost where clinically suitable, while access to certain newer lipid-lowering therapies is conditional on commercial or patient access arrangements.[1][8][3][9]

• Select a high-intensity statin with low acquisition cost when prescribing statin therapy.[1]
• Prescribe ezetimibe co-administered with a statin on the basis of lowest acquisition cost.[8][3]
• Make bempedoic acid with ezetimibe available only where the specified company commercial arrangement is in place.[3]
• Provide evolocumab and alirocumab only where the relevant agreed patient access scheme discount is available.[3][9]
• Continue treatment initiated before publication of the relevant guidance for bempedoic acid with ezetimibe, evolocumab or alirocumab under existing funding arrangements until the patient and National Health Service clinician consider stopping appropriate.[3][9]
• Enable local implementation through healthcare commissioners and providers, taking account of local and national funding and service-development priorities.[10]
• Provide funding for applicable technology appraisal recommendations where patients and professionals wish to use them, in line with the National Health Service Constitution.[10]

No monetary treatment prices, budgets, allocations, funding-gap estimates, resource-mobilisation targets or wider economic assumptions are specified.[2][6][7][8][3][9][10]